Article Text

Download PDFPDF
DI-062 Sustained virologic response rates of new direct acting antiviral agents for HCV
  1. C Caballero Requejo1,
  2. M Onteniente Candela1,
  3. JJ Franco Miguel1,
  4. M Garcia Coronel1,
  5. A Trujillano Ruiz1,
  6. M Gil Candel1,
  7. C Garcia-Molina Saez1,
  8. F Artime Rodriguez-Hermida2
  1. 1Hospital General Universitario Reina Sofía, Pharmacy, Murcia, Spain
  2. 2Hospital Universitario Virgen de Las Nieves, Granada, Spain


Background The primary goal of hepatitis C virus (HCV) therapy is to cure the infection. A sustained virological response (SVR) is defined as undetectable HCV RNA 12 weeks (SVR12) after treatment completion.

Purpose To assess the effectiveness of new direct acting antiviral agents, measuring HCV RNA, 12 weeks after treatment completion.

Material and methods Propective, descriptive, observational study conducted in a referral hospital for a population of 195 000 people, between September 2014 and September 2015. Patients with chronic HCV who had completed treatment with the new direct acting antivirals (DAAs) were selected. Viral load was measured during treatment and 12 weeks after treatment completion. Naïve and previously treated patients, as monoinfected and coinfected with HIV, were included. Demographic and clinical data were obtained from electronic medical records. The pharmacist followed-up patients, assessing treatment efficacy by the value for viral load.

Results 86 patients completed treatment during the study period, but only SVR12 data were obtained in 35 patients, which were included in the study. 65.7% were male and mean age was 55.8 ± 8 years. 74.3% of patients were from the gastroenterology department and 25,7% from the infectious diseases department, and 11.4% were coinfected with HIV. 85.7% of patients had liver fibrosis F4, measured with Fibroscan. Regarding previous treatment, 68.6% of patients were treated with interferon (IFN) and ribavirin, and 11.4% were treated with triple therapy regimens, being 31.4% non-responders, 28.6% relapsers, 11.4% intolerant to interferon and 8.6% partial responders. 20% were naïve. Genotype 1b was the most prevalent genotype (37.1%), followed by genotype 1a (22.9%). Treatment with DAAs was distributed as follows: 51.4% sofosbuvir with simeprevir; 31.4% sofosbuvir; 5.7% sofosbuvir with daclatasvir; 5.7% simeprevir; and 5.7% dasabuvir, ombitasvir, paritaprevir and ritonavir. 65.7% were IFN free combinations. 85.7% were treated for 12 weeks, while 14.3% were treated for 24 weeks. 68.6% of patients had a high baseline HCV RNA level (>800 000 IU/mL). At treatment completion, 100% of patients had undetectable viral load. 91.4% of them achieved SVR12.

Conclusion DAAs showed high SVR12 rates (91.4%), and therefore constitute an effective treatment for HCV.

References and/or Acknowledgements Pharmacy department.

No conflict of interest.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.